Table 2

Baseline characteristics of participants and mortality from CVD, non-CVD, and all causes according to FPG and 2-h plasma glucose categories

MenWomen
Group I: 2-h PG ≤ FPGGroup II: 2-h PG > FPGGroup I: 2-h PG ≤ FPGGroup II: 2-h PG > FPG
n (%)6,663 (53.0)5,903 (47.0)4,096 (37.7)6,778 (62.3)
Age (years)52 (52–53)55 (55–55)52 (52–53)54 (54–54)
BMI (kg/m2)25.5 (25.4–25.6)25.9 (25.8–26.0)25.4 (25.3–25.6)26.0 (25.9–26.1)
FPG (mmol/l)5.3 (5.3–5.3)5.2 (5.2–5.2)5.2 (5.2–5.3)5.2 (5.2–5.2)
2-h PG (mmol/l)4.3 (4.3–4.4)6.2 (6.2–6.3)4.5 (4.5–4.5)6.3 (6.3–6.3)
Fasting insulin (pmol/l)*−0.03 (−0.06 to 0)0.08 (0.05–0.11)−0.11 (−0.14 to −0.08)0.04 (0.01–0.07)
Total cholesterol (mmol/l)6.2 (6.2–6.3)6.2 (6.2–6.2)6.2 (6.2–6.3)6.3 (6.2–6.3)
Blood pressure (mmHg)
    Systolic131 (130–131)133 (133–134)128 (128–129)132 (132–133)
    Diastolic81 (81–82)83 (83–83)78 (77–78)80 (80–80)
Current smoking (%)23.420.223.917.9
Hypertension (%)35.647.134.345.2
Mortality per 1,000 person years (n)
    CVD5.4 (378)7.4 (449)1.4 (59)2.3 (187)
    Non-CVD4.3 (299)5.1 (312)2.8 (122)2.9 (229)
    All-cause9.7 (677)12.5 (761)4.2 (181)5.2 (416)
  • Data are n (%) or age- and study-adjusted means (95% CIs).

  • *9,978 men and 7,350 women with z score transformation.

  • P < 0.001 for different between groups in men and women.